Company / Current Liabilities
Aquestive Therapeutics, Inc. Current Liabilities History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$47.6M
FY2025
5-year range
$18.3M / $47.6M
FY2021-FY2025
Trend
+152.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 8 years, ranging from $18M in FY2023 to $48M in FY2025.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of +17.7%.
Increased from $18M to $48M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.7%, indicating consistent growth.
- In FY2025, current liabilities increased 152.4% year-over-year.
- Lowest current liabilities in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.6M | +152.4% |
| FY2024 | $18.9M | +3.0% |
| FY2023 | $18.3M | -53.7% |
| FY2022 | $39.5M | +80.0% |
| FY2021 | $22.0M | +4.1% |
| FY2020 | $21.1M | +13.7% |
| FY2019 | $18.6M | -43.7% |
| FY2018 | $33.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026